Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 1901756.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The cardiovascular, renal, pulmonary, and dermatologic toxicities of interleukin-2 (IL-2) and gamma-interferon (IFN) are well described. However, autoimmune toxicities have only recently been noticed. The authors report the development of warm autoantibodies against erythrocytes in a patient receiving IL-2 (3.75 x 10(6) cetus units/m2 intravenous bolus three times per week) and gamma-IFN (0.1 mg/m2 subcutaneously three times per week) for metastatic renal cell carcinoma. Other potential causes of autoantibody formation, such as drugs, infection, and collagen vascular disease, were excluded. Both gamma-IFN and IL-2 have the potential to trigger or exacerbate autoimmunity due to either aberrant expression of restricted antigens or inhibition of normal cellular immune suppressor mechanisms.
Medical subject headings
- Autoantibodies
- Carcinoma, Renal Cell
- Erythrocytes
- Interferon-gamma
- Interleukin-2
- Kidney Neoplasms